Neogenomics Inc
NEO
Detailliertes Diagramm anzeigen
8.620USD
+0.510+6.29%
Handelsschluss 09/18, 16:00（ET）Kurse um 15 Minuten verzögert
1.11BMarktkapitalisierung
VerlustKGV TTM
Intraday
1m
30m
1h
D
W
M
D
Heute
+6.29%
5 Tage
+15.24%
1 Monat
+38.81%
6 Monate
-12.40%
Seit Jahresbeginn
-47.69%
1 Jahr
-47.08%
Detailliertes Diagramm anzeigen
TradingKey Aktien-Score
Währung: USD Aktualisiert：2025-09-17Wichtige Einblicke
Die Fundamentaldaten des Unternehmens sind relativ gesund. Seine Bewertung wird als angemessen bewertet angesehen,und die institutionelle Anerkennung ist sehr hoch. In den letzten 30 Tagen haben mehrere Analysten die Aktie mit einer Halten bewertet. Trotz einer sehr schwachen Marktentwicklung zeigt das Unternehmen starke Fundamentaldaten und technische Indikatoren. Der Aktienkurs bewegt sich seitwärts zwischen den Unterstützungs- und Widerstandsniveaus, was ihn für schwankungsorientiertes Trading geeignet macht.
Aktienbewertung
Widerstand & Unterstützung
Keine Daten
Radar Chart
Aktueller Preis
Vorher
Analysten-Ziel
Basierend auf insgesamt
15
Analysten
Halten
Aktuelles Rating
9.591
Kursziel
+20.04%
Aufwärtspotenzial
Hinweis: Analystenbewertungen und Kursziele werden von LSEG ausschließlich zu Informationszwecken bereitgestellt und stellen keine Anlageberatung dar.
Unternehmens-Highlights
HöhepunkteRisiko
NeoGenomics, Inc. provides a range of oncology diagnostic testing and consultative services which includes technical laboratory services. The Company offers professional interpretation of laboratory test results by licensed physicians who specialize in pathology and oncology. Its segments include Clinical Services and Advanced Diagnostics. The Clinical Services segment consists of clinical cancer testing; interpretation and consultative services; molecular and NGS testing, and comprehensive technical and professional services offering. Its Clinical Services customers include community-based pathology and oncology practices, hospital pathology labs, reference labs, and academic centers. The Advanced Diagnostics segment consist of clinical trials and research, validation laboratory services, and informatics. Its Advanced Diagnostics customers include pharmaceutical companies to whom it provides testing and other services to support their research studies and clinical trials.
performance_growth_high
performance_growth_high_desc%!(EXTRA string=29.59%)
valuation_overestimated
valuation_overestimated_desc%!(EXTRA string=PE, string=-9.94)
institutional_decreasing_position
institutional_decreasing_position_desc%!(EXTRA string=126.82M, string=9.26%)
institutional_hold%!(EXTRA string=The Vanguard)
institutional_hold_desc%!(EXTRA string=The Vanguard, string=14.10M)
Nachrichten
Bald gibt es mehr Neuigkeiten, bleiben Sie dran...
Finanzindikatoren
EPS
Keine Daten
Gesamteinnahmen
Keine Daten
Unternehmen
NeoGenomics, Inc. provides a range of oncology diagnostic testing and consultative services which includes technical laboratory services. The Company offers professional interpretation of laboratory test results by licensed physicians who specialize in pathology and oncology. Its segments include Clinical Services and Advanced Diagnostics. The Clinical Services segment consists of clinical cancer testing; interpretation and consultative services; molecular and NGS testing, and comprehensive technical and professional services offering. Its Clinical Services customers include community-based pathology and oncology practices, hospital pathology labs, reference labs, and academic centers. The Advanced Diagnostics segment consist of clinical trials and research, validation laboratory services, and informatics. Its Advanced Diagnostics customers include pharmaceutical companies to whom it provides testing and other services to support their research studies and clinical trials.
BörsenkürzelNEO
UnternehmenNeogenomics Inc
CEOMr. Antony P. Zook
Websitehttps://neogenomics.com/
Verwandte Finanzinstrumente
+0.36%
+0.58%
+2.53%
+0.38%
+0.60%
+3.74%
+11.56%
+0.82%
+0.38%
+1.78%
+0.68%
-0.41%
+0.13%
+1.84%
-0.55%
+1.36%
-1.72%
+1.65%
+2.18%
0.00%
